LYELL IMMUNOPHARMA INC's ticker is LYEL and the CUSIP is 55083R104. A total of 119 filers reported holding LYELL IMMUNOPHARMA INC in Q4 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $36,048 | +302.7% | 24,861 | +519.4% | 0.00% | – |
| Q1 2024 | $8,951 | -86.0% | 4,014 | -87.9% | 0.00% | -100.0% |
| Q4 2023 | $64,100 | +49.4% | 33,041 | +13.2% | 0.00% | 0.0% |
| Q3 2023 | $42,900 | +267.5% | 29,184 | +695.0% | 0.00% | – |
| Q2 2023 | $11,674 | +46596.0% | 3,671 | -65.6% | 0.00% | -100.0% |
| Q1 2023 | $25 | +150.0% | 10,687 | +251.9% | 0.00% | – |
| Q4 2022 | $10 | -100.0% | 3,037 | -64.5% | 0.00% | -100.0% |
| Q3 2022 | $63,000 | +23.5% | 8,546 | +7.9% | 0.00% | 0.0% |
| Q2 2022 | $51,000 | +15.9% | 7,919 | -8.6% | 0.00% | – |
| Q1 2022 | $44,000 | -35.3% | 8,665 | -2.0% | 0.00% | -100.0% |
| Q4 2021 | $68,000 | +83.8% | 8,841 | +256.3% | 0.00% | 0.0% |
| Q3 2021 | $37,000 | – | 2,481 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WuXi AppTec Co., Ltd. | 7,682,156 | $11,139,126 | 47.74% |
| MWG Management Ltd. | 20,162,332 | $29,235,381 | 31.93% |
| Orland Properties Ltd | 15,093,969 | $21,886,255 | 16.63% |
| Foresite Capital Management IV, LLC | 8,325,000 | $12,071,250 | 8.11% |
| Opaleye Management Inc. | 1,670,000 | $2,421,500 | 0.55% |
| MIC Capital Management UK LLP | 1,740,569 | $2,523,825 | 0.55% |
| Alphabet Inc. | 5,865,125 | $8,504,431 | 0.43% |
| HSG Holding Ltd | 3,045,997 | $4,995,435 | 0.18% |
| Orbimed Advisors | 6,405,098 | $9,287,392 | 0.18% |
| Ikarian Capital, LLC | 526,066 | $762,796 | 0.13% |